Evolus (NASDAQ:EOLS) Trading Up 5.9%

Evolus, Inc. (NASDAQ:EOLS) rose 5.9% on Friday . The company traded as high as $14.49 and last traded at $14.40. Approximately 220,301 shares were traded during trading, a decline of 62% from the average daily volume of 577,022 shares. The stock had previously closed at $13.60.

Analyst Upgrades and Downgrades

Several research analysts have commented on EOLS shares. Cantor Fitzgerald reissued an “overweight” rating on shares of Evolus in a research note on Thursday, June 20th. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 target price on shares of Evolus in a research report on Thursday, August 1st. Finally, HC Wainwright restated a “buy” rating and set a $27.00 price target on shares of Evolus in a research report on Thursday, August 1st.

Evolus Price Performance

The company has a debt-to-equity ratio of 6.26, a quick ratio of 2.96 and a current ratio of 2.92. The business has a 50-day simple moving average of $11.85 and a 200 day simple moving average of $12.75. The firm has a market cap of $898.31 million, a P/E ratio of -13.70 and a beta of 1.29.

Insiders Place Their Bets

In other news, Director Vikram Malik sold 7,500 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $12.96, for a total value of $97,200.00. Following the completion of the transaction, the director now owns 246,514 shares in the company, valued at approximately $3,194,821.44. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other Evolus news, Director Vikram Malik sold 7,500 shares of the stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $12.96, for a total value of $97,200.00. Following the completion of the transaction, the director now owns 246,514 shares in the company, valued at $3,194,821.44. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider David Moatazedi sold 155,278 shares of the firm’s stock in a transaction on Wednesday, June 5th. The shares were sold at an average price of $12.92, for a total value of $2,006,191.76. Following the transaction, the insider now directly owns 533,349 shares of the company’s stock, valued at approximately $6,890,869.08. The disclosure for this sale can be found here. 6.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Evolus

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Quest Partners LLC bought a new stake in shares of Evolus in the 2nd quarter worth approximately $43,000. Quarry LP purchased a new position in Evolus during the second quarter valued at $54,000. AJOVista LLC bought a new stake in Evolus in the fourth quarter worth $70,000. Tradition Wealth Management LLC grew its stake in shares of Evolus by 44.8% in the fourth quarter. Tradition Wealth Management LLC now owns 8,000 shares of the company’s stock worth $84,000 after acquiring an additional 2,475 shares during the last quarter. Finally, Sierra Summit Advisors LLC bought a new position in shares of Evolus during the fourth quarter valued at $119,000. Institutional investors own 90.69% of the company’s stock.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.